CompletedNot Applicable

LUTATHERA Injection General Use Result Survey

Japan347 participantsStarted 2021-12-17

Plain-language summary

This study was a multicenter observational study with a central registration system and all-case surveillance system without a control group.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients treated with this drug for the following indications during a certain post-marketing period * Indication: Somatostatin receptor-positive neuroendocrine tumor Patients who started to receive this drug before the contract for this study will also be included in the study population and it will be allowed to register them after the contract so that all patients who receive this drug will be included in this study. Patients treated with this drug for off-label indication will also be included in this study to register all patients received this drug. Exclusion Criteria: * Not applicable

What they're measuring

Proportion of patients with Renal dysfunction, Myelosuppression, Myelodysplastic syndrome/acute myeloid leukaemia and Hormone release induced crises

Timeframe: Until 40 weeks after the date of the last dose (64 weeks if 4 doses are administered 8 weeks apart).

Trial details

NCT IDNCT05844332

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-06-27

View on ClinicalTrials.gov More Somatostatin Receptor-positive Neuroendocrine Tumor trials